Skip to main content
Log in

Barriers to care and treatment experiences among individuals with postpartum psychosis

  • Original Article
  • Published:
Archives of Women's Mental Health Aims and scope Submit manuscript

Abstract

Purpose

Postpartum psychosis (PP) is a severe psychiatric disorder affecting 1–2 per 1,000 deliveries. Prompt access to healthcare and timely initiation of treatment are crucial to minimizing harm and improving outcomes. This analysis seeks to fill gaps in knowledge surrounding barriers to care and treatment experiences among this population.

Methods

Participants were individuals with histories of PP who enrolled in the Massachusetts General Hospital Postpartum Psychosis Project (MGHP3). The MGHP3 Healthcare Access Survey, a cross-sectional questionnaire, assesses barriers to care, treatment-seeking behaviors, and experiences with treatment. Descriptive statistics were utilized to describe sample characteristics.

Results

139 participants provided 146 episode-specific survey responses. Lack of available services was cited as the greatest barrier to care for PP. Among those who sought treatment, obstetric providers (34.5%) and emergency medical professionals (29.4%) were the most common initial points of contact. 82.2% of the respondents went to an emergency room or crisis center during their episode(s). Most (61.8%) reported being given insufficient information to manage their PP. Approximately half of participants were hospitalized (55.5%), the majority of whom had no access to their infant during hospitalization (70.4%). Of those breastfeeding or pumping at admission, 31.3% were not given access to a breast pump. 44.4% dealt with delivery-related medical issues during their hospitalization.

Conclusion

This report is the first of its kind to assess key public health domains among individuals with PP. Findings point to several directions for future research and clinical practice to improve treatment timeliness and quality, potentially improving long-term outcomes related to this serious illness.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

Download references

Funding

This study was supported by the Jeanne and Gerhard Andlinger Research Fund for Innovative Science at Massachusetts General Hospital and The Rosalie Katz Family Foundation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lauren A. Kobylski.

Ethics declarations

Conflicts of interest

Lauren A. Kobylski, MPH, Miranda H. Arakelian, BA, Margaret L. Gaw, BA, and Rachel Vanderkruik, PhD, MSc have no conflicts of interest to disclose. 

Marlene P. Freeman, MD (as of 7/10/2023): Research Support: Dr. Freeman is an employee of Massachusetts General Hospital, and works with the MGH National Pregnancy Registry. MGH National Pregnancy Registry: Current Sponsors: Alkermes, Inc. (2016-Present); Eisai, Inc. (2022-Present); Johnson & Johnson/Janssen Pharmaceuticals, Inc (2019-Present); Otsuka America Pharmaceutical, Inc. (2008-Present); Sage Therapeutics (2019-Present); Supernus Pharmaceuticals (2021-Present); Teva Pharmaceutical Industries Ltd. (2018-Present). As an employee of MGH, Dr. Freeman works with the MGH CTNI, which has had research funding from multiple pharmaceutical companies and NIMH. Other Research Support: SAGE Therapeutics, JayMac. Advisory/Consulting, Data Safety Committees: Independent Data Safety and Monitoring Committees: Janssen (Johnson& Johnson), Novartis, Neurocrine; Advisory Boards: Eliem, Sage; Brainify; Everly Health; Tibi Health; Relmada; Beckley Psytech.

Speaking/Honoraria: WebMD, Medscape, Pri-Med, Postpartum Support International. Royalty/patent, other income: Scale Royalties- through MGH Scale, The Massachusetts Female Reproductive Lifecycle and Hormones Questionnaire.

Lee S. Cohen, MD (as of 1/20/2023): Research Support: Dr. Cohen is an employee of Massachusetts General Hospital, and works with the MGH National Pregnancy Registry. MGH National Pregnancy Registry: Current Sponsors: Alkermes, Inc. (2016-Present); Eisai, Inc. (2022-Present); Johnson & Johnson/Janssen Pharmaceuticals, Inc (2019-Present); Otsuka America Pharmaceutical, Inc. (2008-Present); Sage Therapeutics (2019-Present); Supernus Pharmaceuticals (2021-Present); Teva Pharmaceutical Industries Ltd. (2018-Present). As an employee of MGH, Dr. Cohen works with the MGH CTNI, which has had research funding from multiple pharmaceutical companies and NIMH. Other research support: National Institutes of Health; SAGE Therapeutics. Advisory/Consulting: None. Speaking/Honoraria: None. Royalty/patent, other income: None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Lauren A. Kobylski and Miranda H. Arakelian share co-first authorship

Lee S. Cohen and Rachel Vanderkruik share co-senior authorship

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 35 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kobylski, L.A., Arakelian, M.H., Freeman, M.P. et al. Barriers to care and treatment experiences among individuals with postpartum psychosis. Arch Womens Ment Health (2024). https://doi.org/10.1007/s00737-024-01447-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00737-024-01447-z

Keywords

Navigation